The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Open accessAbstract
One of the main features of Alzheimer's disease (AD) is the severe reduction of the cerebral metabolic rate for glucose (CMRglc). In vivo imaging using positron emission tomography with 2‐[ 18 F]fluoro‐2‐deoxy‐D‐glucose (FDG–PET) demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. Increasing evidence suggests that CMRglc reductions occur at the preclinical stages of AD. CMRglc reductions were observed on FDG–PET before the onset of disease in several groups of at‐risk individuals, including patients with mild cognitive impairment (MCI), often a prodrome to AD; presymptomatic individuals carrying mutations responsible for early‐onset familial AD; cognitively normal elderly individuals followed for several years until they declined to MCI and eventually to AD; normal, middle‐aged individuals who expressed subjective memory complaints and were carriers of the apolipoprotein E epsilon‐4 allele, a strong genetic risk factor for late‐onset AD. However, the causes of the early metabolic dysfunction forerunning the onset of AD are not known. An increasing body of evidence indicates a deficient or altered energy metabolism that could change the overall oxidative microenvironment for neurons during the pathogenesis and progression of AD, leading to alterations in mitochondrial enzymes and in glucose metabolism in AD brain tissue. The present paper reviews findings that implicate hypometabolism and oxidative stress as crucial players in the initiation and progression of synaptic pathology in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Oxidants, antioxidants, and the degenerative diseases of aging.
Ames, B. N., Shigenaga, M. K., & Hagen, T. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.7915 · Cited by 5,958
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C., Sokoloff, L., & Kuhl, D. E. (1979) · Annals of Neurology · doi:10.1002/ana.410060502 · Cited by 2,418
Cited by
Brain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
Astrocytes: a central element in neurological diseases
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J.-M., Parpura, V., Hol, E. M., Sofroniew, M. V., & Verkhratsky, A. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1513-1 · Cited by 755
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?
Bourassa, M. W., Alim, I., Bultman, S. J., & Ratan, R. R. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.009 · Cited by 632
Brain fuel metabolism, aging, and Alzheimer’s disease
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., et al. (2011) · Nutrition · doi:10.1016/j.nut.2010.07.021 · Cited by 614
González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Metabolism and functions of copper in brain
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.01.002 · Cited by 506
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y., Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 502
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Astrocytes in Alzheimer's Disease
Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C.-Y., & Rodriguez, J. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.017 · Cited by 455
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Astrocytes in physiological aging and Alzheimer’s disease
Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., & Verkhratsky, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.007 · Cited by 439
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Oral inflammation and infection, and chronic medical diseases: implications for the elderly
Scannapieco, F. A., & Cantos, A. (2016) · Periodontology 2000 · doi:10.1111/prd.12129 · Cited by 351
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., & Hampel, H. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.005 · Cited by 347
Role of Oxidative Stress in the Progression of Alzheimer's Disease
Sultana, R., & Butterfield, D. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1222 · Cited by 327
Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada-Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves-Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 317
Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
The role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
Immunometabolism in the Brain: How Metabolism Shapes Microglial Function
Bernier, L.-P., York, E. M., & MacVicar, B. A. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.08.008 · Cited by 283
Allaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A., & Magistretti, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5098-09.2010 · Cited by 278
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
The Emerging Link between O-GlcNAc and Alzheimer Disease
Zhu, Y., Shan, X., Yuzwa, S. A., & Vocadlo, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.601351 · Cited by 267
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“The early stages of AD are marked by deficits in cerebral glucose utilization([11-16]) and, as the disease progresses, the metabolic and physiological abnormalities worsen.”
BackgroundMultifunctional role of astrocytes as gatekeepers of neuronal energy supply
Stobart, J. L., & Anderson, C. M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00038 · Cited by 264
Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging
Wrigley, S., Arafa, D., & Tropea, D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00014 · Cited by 258
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Müller, W. E., Eckert, A., Kurz, C., Eckert, G. P., & Leuner, K. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8141-5 · Cited by 243
Villain, N., Fouquet, M., Baron, J.-C., Mezenge, F., Landeau, B., de La Sayette, V., Viader, F., Eustache, F., Desgranges, B., & Chetelat, G. (2010) · Brain · doi:10.1093/brain/awq203 · Cited by 237
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
Chen, H.-K., Ji, Z.-S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.151084 · Cited by 209
The energetic brain—A review from students to students
Bordone, M. P., Salman, M. M., Titus, H. E., Amini, E., Andersen, J. V., Chakraborti, B., Diuba, A. V., Dubouskaya, T. G., Ehrke, E., Espindola de Freitas, A., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14829 · Cited by 205
“Impeded cerebral glucose metabolism has been found in patients with T2DM; a condition commonly observed in Alzheimer patients (see below) (Mosconi et al. 2008; Baker et al. 2011).”
BackgroundEckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177
“Brain imaging studies have demonstrated defects in glucose use in living AD patients, an abnormality that may occur well before the onset of clinical symptoms [17].”
BackgroundGray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163
Bukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits
Tong, X.-K., Lecrux, C., & Hamel, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0169-12.2012 · Cited by 160
Smilansky, A., Dangoor, L., Nakdimon, I., Ben-Hail, D., Mizrachi, D., & Shoshan-Barmatz, V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691493 · Cited by 143
“Glucose hypometabolism not only limits the metabolic capabilities of the cell, it also leads to oxidative stress, known to play a major role in Alzheimer disease (64).”
BackgroundDiabetes drugs in the fight against Alzheimer's disease
Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142
Glia in the pathogenesis of neurodegenerative diseases
Verkhratsky, A., Parpura, V., Pekna, M., Pekny, M., & Sofroniew, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140107 · Cited by 141
Ott, V., Benedict, C., Schultes, B., Born, J., & Hallschmid, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01490.x · Cited by 139
Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease
Croteau, E., Castellano, C.-A., Richard, M. A., Fortier, M., Nugent, S., Lepage, M., Duchesne, S., Whittingstall, K., Turcotte, É. E., Bocti, C., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180202 · Cited by 135
Glycolytic Metabolism, Brain Resilience, and Alzheimer’s Disease
Zhang, X., Alshakhshir, N., & Zhao, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.662242 · Cited by 134
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Oligemic Hypoperfusion Differentially Affects Tau and Amyloid-β
Koike, M. A., Green, K. N., Blurton-Jones, M., & LaFerla, F. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090750 · Cited by 130
Lactate deficit in an Alzheimer disease mouse model: the relationship with neuronal damage
Zhang, M., Cheng, X., Dang, R., Zhang, W., Zhang, J., & Yao, Z. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly102 · Cited by 130
“In particular, alterations in cerebral glucose metabolism, including glycolysis and oxidative metabolism, have been identified in individuals of familial AD before the manifestation of Ab plaques (6, 7).”
Backgroundvan Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain
Hardas, S. S., Sultana, R., Clark, A. M., Beckett, T. L., Szweda, L. I., Murphy, M. P., & Butterfield, D. A. (2013) · Redox Biology · doi:10.1016/j.redox.2013.01.002 · Cited by 120
“The raw homogenates were centrifuged at 2500xg, for 10 min at 4 1C and supernatants were collected.”
MethodPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Pawlosky, R. J., Kemper, M. F., Kashiwaya, Y., King, M. T., Mattson, M. P., & Veech, R. L. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13958 · Cited by 108
Altered whole-brain white matter networks in preclinical Alzheimer's disease
Fischer, F. U., Wolf, D., Scheurich, A., & Fellgiebel, A. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.007 · Cited by 105
Andersen, J. V., Skotte, N. H., Christensen, S. K., Polli, F. S., Shabani, M., Markussen, K. H., Haukedal, H., Westi, E. W., Diaz-delCastillo, M., Sun, R. C., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04237-y · Cited by 104
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ1–42 and NOX activation
Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., McMullen, J. M., Davis, P. R., Murphy, M. P., Van Eldik, L. J., St Clair, D., & Keller, J. N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.012 · Cited by 96
“Markers of oxidative stress are elevated in mild cognitive impairment (MCI), which may be the earliest stage of clinical dementia (Keller et al., 2005), (Williams et al., 2006), (Butterfield et al., 2006), (Mosconi et al., 2008).”
Verkhratsky, A., Marutle, A., Rodríguez-Arellano, J. J., & Nordberg, A. (2015) · The Neuroscientist · doi:10.1177/1073858414547132 · Cited by 95
Selective Oestrogen Receptor Modulators Differentially Potentiate Brain Mitochondrial Function
Irwin, R. W., Yao, J., To, J., Hamilton, R. T., Cadenas, E., & Brinton, R. D. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02251.x · Cited by 92
Cortical Thinning in Individuals with Subjective Memory Impairment
Meiberth, D., Scheef, L., Wolfsgruber, S., Boecker, H., Block, W., Träber, F., Erk, S., Heneka, M. T., Jacobi, H., Spottke, A., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142322 · Cited by 84
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85
Self-citationIron Deposition Leads to Hyperphosphorylation of Tau and Disruption of Insulin Signaling
Wan, W., Cao, L., Kalionis, B., Murthi, P., Xia, S., & Guan, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00607 · Cited by 84
Kodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
“the findings that brain hypometabolism is a major feature of AD [64,71,72].”
BackgroundResultInfluentialCao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation
Nilsen, L. H., Rae, C., Ittner, L. M., Götz, J., & Sonnewald, U. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.212 · Cited by 62
Malkov, A., Popova, I., Ivanov, A., Jang, S.-S., Yoon, S. Y., Osypov, A., Huang, Y., Zilberter, Y., & Zilberter, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02551-x · Cited by 59
Fuller, J. T., Cronin-Golomb, A., Gatchel, J. R., Norton, D. J., Guzmán-Vélez, E., Jacobs, H. I. L., Hanseeuw, B., Pardilla-Delgado, E., Artola, A., Baena, A., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.6 · Cited by 57
Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach
Schelke, M. W., Hackett, K., Chen, J. L., Shih, C., Shum, J., Montgomery, M. E., Chiang, G. C., Berkowitz, C., Seifan, A., Krikorian, R., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13070 · Cited by 51
Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“…(Muddapu et al., 2020), as evident in the brains of both AD (Lyingtunell et al., 1981; Hoyer et al., 1988; Ogawa et al., 1996; Drzezga et al., 2003; Mosconi et al., 2008) and PD patients (Huang et al., 2008; Hosokai et al., 2009; Liepelt et al., 2009; Borghammer et al., 2010; Berti et al., 2012).”
BackgroundHartl, D., Schuldt, V., Forler, S., Zabel, C., Klose, J., & Rohe, M. (2012) · Journal of Proteome Research · doi:10.1021/pr300021e · Cited by 48
Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2230-9 · Cited by 45
Amyloid β 1-42 Induces Hypometabolism in Human Stem Cell-Derived Neuron and Astrocyte Networks
Tarczyluk, M. A., Nagel, D. A., Parri, H. R., Tse, E. H., Brown, J. E., Coleman, M. D., & Hill, E. J. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.58 · Cited by 42
Carroll, C. M., & Macauley, S. L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00258 · Cited by 32
Astrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Montesanto, A., Crocco, P., Anfossi, M., Smirne, N., Puccio, G., Colao, R., Maletta, R., Passarino, G., Bruni, A. C., & Rose, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150993 · Cited by 24
Fitzgerald, G. S., Chuchta, T. G., & McNay, E. C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14160 · Cited by 22
Song, I.-U., Choi, E. K., Oh, J. K., Chung, Y.-A., & Chung, S.-W. (2016) · Acta Radiologica · doi:10.1177/0284185114566088 · Cited by 17
“FDGPET studies in patients with AD have demonstrated consistent and progressive cerebral metabolic reductions, the extent and topography of which correlate with symptom severity (2,19).”
BackgroundResultInfluentialHerbet, M., Natorska‑Chomicka, D., Korga, A., Ostrowska, M., Izdebska, M., Gawrońska‑Grzywacz, M., Piątkowska‑Chmiel, I., Pawłowski, K., Ślaska, B., Poleszak, E., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9865 · Cited by 17
“On the other hand, it has been shown that serotonin systems are involved in the control of brain glucose delivery, transport, and uptake (48).”
BackgroundHuang, Q., Voloudakis, G., Ren, Y., Yoon, Y., Zhang, E., Kajiwara, Y., Shao, Z., Xuan, Z., Lebedev, D., Georgakopoulos, A., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201700447rr · Cited by 17
Zhang, M., Wang, Y., Xu, X., Dai, L., Chen, X., Wang, K., Bai, Y., & Guo, H. (2022) · doi:10.21203/rs.3.rs-1780387/v1 · Cited by 1
Metadata
- Authors
- Mosconi, L., Pupi, A., & De Leon, M. J.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-12
- Volume
- 1147
- Issue
- 1
- Pages
- 180-195
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2031155126
- Cited by
- 595
- References
- 103
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.